Merck buys rights to NewLink's experimental Ebola vaccine
Nov 24 (Reuters) - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.
Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement.
Financial details were not disclosed.
The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug.
The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015. (Reporting by Vidya L Nathan in Bangalore; Editing by Siddharth Cavale)
© Thomson Reuters 2017 All rights reserved.